Hongbing Ma

机构：Sichuan University, West China Hospital of Sichuan University

发表论文 9 篇 · 总被引 21 次 · h-index 3

代表论文

• RNA sequencing of myeloid sarcoma, shed light on myeloid sarcoma stratification (2023 · Cancer Medicine · 被引 9)
• Lisaftoclax (APG-2575), a Novel BCL-2 Inhibitor, in Combination with Azacitidine in Treatment of Patients with Myelodysplastic Syndrome (MDS) (2024 · Blood · 被引 3)
• Safety and Efficacy of Lisaftoclax (APG-2575), a Novel BCL-2 Inhibitor (BCL-2i), in Relapsed or Refractory (R/R) or Treatment-Naïve (TN) Patients (Pts) with Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), or Other Myeloid Neoplasms (2023 · Blood · 被引 3)
• Safety and efficacy of lisaftoclax, a novel BCL-2 inhibitor, in combination with azacitidine in patients with treatment-naïve or relapsed or refractory acute myeloid leukemia. (2024 · Journal of Clinical Oncology · 被引 2)
• False positive results: a challenge for laboratory physicians and hematologists in treating multiple myeloma with daratumumab (2022 · Hematology · 被引 2)
• CSF3R Mutations Imply Adverse Prognostic Impact in Adult Acute Myeloid Leukemia Patients: A Single‐Center Retrospective Study (2025 · Cancer Medicine · 被引 1)